Hence, MIF might have both pro-tumorigenic and anti-tumorigenic effects, depending on determined circumstances: first, the cells by which it is produced, stromal versus tumour ones; second, the microenvironment and the cytokine milieu; third the effects might be related to the dose, being protumoral either at excessively low or high levels; fourth, post-translational modifications, such as glycosylation or N-cysteinylation, partially influenced by ROS levels [92]. The gene discussed is MIF; the disease is neoplasm.